Business Description
ACADIA Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US0042251084
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 11.45 | |||||
Equity-to-Asset | 0.59 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | 0.4 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.88 | |||||
Beneish M-Score | -2.55 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.4 | |||||
3-Year EBITDA Growth Rate | 38.8 | |||||
3-Year EPS without NRI Growth Rate | 40.9 | |||||
3-Year FCF Growth Rate | 46.1 | |||||
3-Year Book Growth Rate | -12.6 | |||||
Future 3-5Y Total Revenue Growth Rate | 16.17 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.29 | |||||
Quick Ratio | 2.11 | |||||
Cash Ratio | 1.64 | |||||
Days Inventory | 235.21 | |||||
Days Sales Outstanding | 38.31 | |||||
Days Payable | 82.57 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1 | |||||
Shareholder Yield % | -0.23 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 91.61 | |||||
Operating Margin % | 12.08 | |||||
Net Margin % | 13.83 | |||||
FCF Margin % | 21.81 | |||||
ROE % | 27.32 | |||||
ROA % | 15.57 | |||||
ROIC % | 51.02 | |||||
ROC (Joel Greenblatt) % | 203.67 | |||||
ROCE % | 21.17 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 22.01 | |||||
Forward PE Ratio | 33.1 | |||||
PE Ratio without NRI | 22.01 | |||||
Price-to-Owner-Earnings | 21.44 | |||||
PEG Ratio | 0.99 | |||||
PS Ratio | 3.07 | |||||
PB Ratio | 4.95 | |||||
Price-to-Tangible-Book | 6.05 | |||||
Price-to-Free-Cash-Flow | 14.02 | |||||
Price-to-Operating-Cash-Flow | 14.02 | |||||
EV-to-EBIT | 20.75 | |||||
EV-to-Forward-EBIT | 17.27 | |||||
EV-to-EBITDA | 18.7 | |||||
EV-to-Forward-EBITDA | 41.51 | |||||
EV-to-Revenue | 2.51 | |||||
EV-to-Forward-Revenue | 4.38 | |||||
EV-to-FCF | 11.3 | |||||
Price-to-Graham-Number | 2.44 | |||||
Price-to-Net-Current-Asset-Value | 7.34 | |||||
Price-to-Net-Cash | 17.17 | |||||
Earnings Yield (Greenblatt) % | 4.82 | |||||
FCF Yield % | 7.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
ACADIA Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil MXN) | 16,733.214 | ||
EPS (TTM) (MXN) | 14.049 | ||
Beta | 0.3 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR (MXN) | 0 | ||
20-Day SMA (MXN) | 509 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (MXN) | 509 - 509 | ||
Shares Outstanding (Mil) | 166.39 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
ACADIA Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
ACADIA Pharmaceuticals Inc Stock Events
Event | Date | Price(MXN) | ||
---|---|---|---|---|
No Event Data |
ACADIA Pharmaceuticals Inc Frequently Asked Questions
What is ACADIA Pharmaceuticals Inc(MEX:ACAD)'s stock price today?
When is next earnings date of ACADIA Pharmaceuticals Inc(MEX:ACAD)?
Does ACADIA Pharmaceuticals Inc(MEX:ACAD) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |